Bye bye Sumitomo

[anonymous]

If Myovant reps made more, it’s because we are superior reps

 

[anonymous]

If Myovant reps made more, it’s because we are superior reps

Hahahahahahah

 

[anonymous]

How bad did Urovant get hit in reorg?

 

[anonymous]

If Myovant reps made more, it’s because we are superior reps

Nobody saying you made more. Saying you got chopped up more than others.

 

[anonymous]

How bad did Urovant get hit in reorg?

Becoming Sumitomo is how hard Urovant got hit. Should have stayed solo.

 

[anonymous]

Becoming Sumitomo is how hard Urovant got hit. Should have stayed solo.

The sales growth slowed before the merger.

 

[anonymous]

Fake news. Live meetings in April.

What's fake news? If you could read you'd see I said the NSM has shifted to virtual. Never mentioned anything about the POA.

 

[anonymous]

The sales growth slowed before the merger.

Specialty was at 109% to goal. You're incorrect.

 

[anonymous]

Specialty was at 109% to goal. You're incorrect.

Typical Monday morning QB BS. Sure pal everybody wins the game on Monday. clown

 

[anonymous]

Typical Monday morning QB BS. Sure pal everybody wins the game on Monday. clown

What are you even saying? The stat is wrong?

 

[anonymous]

Mayday mayday the Sumitomo aircraft carrier is going under.

 

[anonymous]

Specialty was at 109% to goal. You're incorrect.

when you look back at the financial reports from last year, they grouped the Vant sales with “other” which over-inflated the whole category against the forecasted goals. What was included in “Other” were things like big milestone payments from Pfizer for FDA approval, selling off ownership rights and other misc things that didn’t have to do with the Vant drugs commercial performance. It’s all in the notes in those slides.

 

[anonymous]

when you look back at the financial reports from last year, they grouped the Vant sales with “other” which over-inflated the whole category against the forecasted goals. What was included in “Other” were things like big milestone payments from Pfizer forFDA approval, selling off ownership rights and other misc things that didn’t have to do with the Vant drugs commercial performance. It’s all in the notes in those slides.

Yup spinning off the #’s. Vant companies were not very profitable to the organization.

 

[anonymous]

The leadership at all levels are the ones who ran this company into the ground. Inexcusable!

 

[anonymous]

How bad did Urovant get hit in reorg?

They’re next in line. They just lost their SVP WJ. The walls are caving in for the uro team. Glad I took the MSPEC job for now. Don’t think this is a safe place to be unless you’re oncology.

 

[anonymous]

Clearly the Japs are working their plan to divest themselves of the US commercial organization. Psych, neuro and Myovant division exit plans almost completed. Gemtesa and Urovant next on the clock. Expect those to be washed away within next 12-18 months. Japs will carve it down to Oncology only and then sell them off within 2-3 years. Game Over soon enough.

 

[anonymous]

Clearly the Japs are working their plan to divest themselves of the US commercial organization. Psych, neuro and Myovant division exit plans almost completed. Gemtesa and Urovant next on the clock. Expect those to be washed away within next 12-18 months. Japs will carve it down to Oncology only and then sell them off within 2-3 years. Game Over soon enough.

Oncology and regenerative medicine

 

[anonymous]

Oncology and regenerative medicine

Yes this is what company will be dwindled down too in the US within next 2 years.

 

[anonymous]

Are we getting new company cell phones next week?

 

[anonymous]

I don’t even care anymore. Company scares me…letting ppl go left and right. Can’t even give an answer for reps in women’s health as to chairmans Circle. Will it exist as half our reps were let go. Please, if you want to keep those working hard, we demand those answers. We are salespeople who have worked our asses off for your company